Actavis expands the world's only pharmaceutical manufacturing facility completely powered by renewable energy
- Zero carbon footprint for tablet manufacturing and packaging
Reykjavik, Iceland, 14 January 2011 - Actavis Group, the world's fourth largest generic pharmaceutical company, today formally opened a new expansion to its pharmaceutical manufacturing site in Iceland. Powered solely by geothermal energy, giving it a zero carbon footprint for tablet manufacturing and packaging, the site uses no fossil fuels. The facility is fully accredited to supply the EU market.
The opening ceremony was attended by the President of Iceland, Olafur Ragnar Grimsson and members of parliament.
Claudio Albrecht, CEO Actavis:
"The site is 100% powered by geothermal energy, and is therefore the most eco-friendly pharmaceutical facility in the world. It meets both the ISO14001 environmental standard and the OHSAS18001 health- and safety standard, reflecting the strong Environment, health and safety commitment of our company. This latest investment increases the production capacity in Iceland by 50%, giving us a significantly increased launch capability for the EU market. This is our principal development and launch site for Europe. We're proud to be able create jobs in Iceland by expanding this site."
Following the expansion the production capacity of the Hafnarfjordur, Iceland site is about 1.5 billion tablets, around 96% of which are exported to the European markets. The Group's investment on the expansion is about EUR 8M.
Actavis operates 14 manufacturing sites in 12 different countries: US, Bulgaria, Iceland, China, Italy, India, Indonesia, Malta, Romania, Russia, Serbia, and the UK. The Group's total production capacity is the equivalent of about 24bn tablets.
Enquiries
Frank Staud
Executive Vice President - Corporate Communications
Tel: +41 79 2309 578
E-mail: [email protected]
Hjordis Arnadottir
Director - External Communications
Tel: +354 840 7476 / +41 79 909 7336
E-mail: [email protected]
About Actavis Group
Actavis is one of the world's leading generic pharmaceutical companies specializing in the development, manufacture and sale of generic pharmaceuticals. The company has operations in more than 40 countries, with 10,000 employees. For further information on Actavis Group, please visit www.actavis.com
Any statements contained in this press release that refer to Actavis' estimated or anticipated future results or future activities are forward-looking statements which reflect the Company's current analysis of existing trends, information and plans. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially depending on factors such as the availability of resources, the timing and effect of regulatory actions, the success of new products, the strength of competition, the success of research and development issues, unexpected contract breaches or terminations, exposure to product liability and other lawsuits, the effect of currency fluctuations and other factors.